Pharmacoeconomic analysis of biologics and methotrexate for rheumatoid arthritis from the standpoint of the number needed to treat concept under the Japanese health insurance system

Table 4 Adjusted number of patient remissions in DAS28-ESR and CDAI and calculated NNT

DAS28-ESR	N	Adjusted patient number of remissions	Remission rate	ARR	NNT	Mean cost per adjusted NNT^a
bDMARDs	55	43	0.782	0.175	5.71	56,152
MTX	66	47	0.712	0.105	9.52	6807

CDAI	N	Adjusted patient number of remissions	Remission rate	ARR	NNT	Mean cost per adjusted NNT*
bDMARDs	55	26	0.473	0.259	3.86	37,959
MTX	66	21	0.318	0.104	9.62	6878

bDMARDS biologic disease-modifying anti-rheumatic drugs, ARR absolute risk reduction, CDAI clinical disease activity index, DAS28-ESR disease activity score in 28 joints using erythrocyte sedimentation rate, MTX methotrexate, NNT number needed to treat
^aUS$/24 weeks/patient

ISSN: 1478-7547